CROSSJECT Successfully Raises €5.7 Million in Capital Increase
CROSSJECT, a rising name in specialty pharmaceuticals, has successfully completed a capital increase totaling more than €5.7 million. This achievement comes after a full exercise of the extension clause, indicating strong investor confidence and demand in the company’s growth potential.
Exciting Details of the Capital Increase
The capital increase witnessed a remarkable total demand of over €9.2 million, translating to an oversubscription rate reaching 1.84 times. Notably, this transaction was significantly supported by Gemmes Venture along with investments from the new investor, Vatel Capital, highlighting the collaborative effort in fostering investor trust and commitment to the company's future.
Context of Financial Needs
The funds raised will play a critical role in completing the final phases of registration and initial production of ZEPIZURE®, an emergency treatment designed for managing epileptic seizures. Currently advancing through late-stage clinical and regulatory development, ZEPIZURE® utilizes the award-winning ZENEO® needle-free auto-injector technology, making it accessible and easy to administer in emergency situations.
Chairman's Insights
Patrick Alexandre, Chairman of the Management Board, expressed gratitude towards the shareholders for their enthusiastic participation, which surpassed initial expectations. He emphasized confidence in entering the final steps of ZEPIZURE®’s development journey, especially with the financial foundation now secured for pre-commercialization efforts.
Objectives and Strategic Moves
Looking ahead, CROSSJECT is focused on preparing for the Emergency Use Authorization (EUA) submission to the FDA, with a well-structured timeline for the validation batch productions that are set to proceed. Collaboration with the Biomedical Advanced Research and Development Authority (BARDA) aligns with the company's strategic interests in ensuring national preparedness against chemical threats through the CHEMPACK program.
Utilization of Funds
In terms of allocation, approximately 60% of the net proceeds from the offering will directly support the final development phases of ZEPIZURE® and its initial production stages. The remaining 40% is earmarked for financing research and development projects related to other promising products, including ZENEO® Adrenaline and ZENEO® Hydrocortisone, and to manage overall operational costs.
Evaluating Future Financial Flexibility
With the capital secured, CROSSJECT anticipates that its current net working capital will be adequate to meet obligations through the end of 2025, assuming timely payments from its U.S. partner following initial deliveries. The company remains vigilant, evaluating both dilutive and non-dilutive financing options to ensure robust cash flow management.
Upcoming SEC Filings
A major highlight will be the expected filing for the second NDA in the second quarter of 2026, showcasing CROSSJECT's commitment to diversifying its product offerings and enhancing its pipeline with innovative solutions. The funds bolster CROSSJECT's preparedness to meet its ambitious objectives effectively.
Company's Capital Structure Post-Increase
Following the completion of the capital increase, CROSSJECT's share capital will amount to approximately €5,032,022.40, representing a significant step toward solidifying its market presence and capabilities within the pharmaceutical sector.
Conclusion and Future Prospects
CROSSJECT is embarking on a promising journey to enhance its position in the pharmaceutical landscape with the successful capital raise. As the company pushes forward, it remains dedicated to innovation and addressing critical healthcare needs through its unique product line, notably the groundbreaking ZEPIZURE® treatment.
Frequently Asked Questions
What is the purpose of the €5.7 million capital increase?
The funds are aimed at supporting the final registration phases of ZEPIZURE® and the start-up of initial production stages, enhancing operational capabilities.
How did the market respond to the capital increase?
The market showcased strong demand, with total subscriptions exceeding €9.2 million, leading to an oversubscription rate of 1.84 times.
What percentage of the funds will be allocated to ZEPIZURE®?
Approximately 60% of the proceeds will be directed towards the final development phases of ZEPIZURE® and related inventory buildup.
Who supported the capital increase?
The transaction received backing from Gemmes Venture and new investor Vatel Capital, among others, demonstrating investor confidence in CROSSJECT’s strategy.
What are CROSSJECT’s future plans with its other product candidates?
The company intends to advance development projects for ZENEO® Adrenaline and ZENEO® Hydrocortisone while maintaining its focus on ZEPIZURE®.
